LY3022859 is an anti-TβRII IgG1 monoclonal antibody blocking TGFβ binding to the ectodomain of TβRII that showed significant antitumor function against primary tumor growth and metastasis in several mice tumor models.194 When tested for use in the treatment of advanced solid tumors in a phase 1 clinical trial, the maximum-tolerated dose for this antibody was not determined since the patients suffered from uncontrolled cytokine release despite prophylaxis.195. Here, TGFB1 is linked to neoplasm.